SK279130B6 - Vo vode vysoko rozpustná, stabilná kryštalická soľ - Google Patents
Vo vode vysoko rozpustná, stabilná kryštalická soľ Download PDFInfo
- Publication number
- SK279130B6 SK279130B6 SK2372-90A SK237290A SK279130B6 SK 279130 B6 SK279130 B6 SK 279130B6 SK 237290 A SK237290 A SK 237290A SK 279130 B6 SK279130 B6 SK 279130B6
- Authority
- SK
- Slovakia
- Prior art keywords
- dideoxy
- stable
- salt
- didehydrothymidine
- preparation
- Prior art date
Links
- 150000003839 salts Chemical class 0.000 title claims abstract description 21
- 238000000034 method Methods 0.000 title claims abstract description 5
- 238000002360 preparation method Methods 0.000 title abstract description 4
- 239000008177 pharmaceutical agent Substances 0.000 title abstract 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 title description 9
- 239000007864 aqueous solution Substances 0.000 claims abstract description 5
- 150000001767 cationic compounds Chemical class 0.000 claims abstract 3
- 229910001411 inorganic cation Inorganic materials 0.000 claims abstract 3
- 150000002892 organic cations Chemical class 0.000 claims abstract 3
- 239000000243 solution Substances 0.000 claims description 11
- 239000004480 active ingredient Substances 0.000 claims description 10
- 150000001875 compounds Chemical class 0.000 claims description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 230000000840 anti-viral effect Effects 0.000 claims description 7
- 239000007788 liquid Substances 0.000 claims description 5
- 239000011734 sodium Substances 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical group C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 3
- 239000003085 diluting agent Substances 0.000 claims description 3
- 229910052708 sodium Inorganic materials 0.000 claims description 3
- 239000003443 antiviral agent Substances 0.000 abstract description 5
- 238000006243 chemical reaction Methods 0.000 abstract description 2
- 239000012266 salt solution Substances 0.000 abstract description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 12
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 12
- 238000011282 treatment Methods 0.000 description 11
- 159000000000 sodium salts Chemical class 0.000 description 10
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 9
- 241000700605 Viruses Species 0.000 description 9
- 201000010099 disease Diseases 0.000 description 8
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 8
- 239000000203 mixture Substances 0.000 description 7
- 238000011321 prophylaxis Methods 0.000 description 7
- 230000003612 virological effect Effects 0.000 description 7
- 239000000126 substance Substances 0.000 description 6
- 150000007523 nucleic acids Chemical class 0.000 description 5
- 102000039446 nucleic acids Human genes 0.000 description 5
- 108020004707 nucleic acids Proteins 0.000 description 5
- 208000030507 AIDS Diseases 0.000 description 4
- 241000725303 Human immunodeficiency virus Species 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- 208000015181 infectious disease Diseases 0.000 description 4
- 229920001223 polyethylene glycol Polymers 0.000 description 4
- 241001430294 unidentified retrovirus Species 0.000 description 4
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 3
- 241000282412 Homo Species 0.000 description 3
- 241000598436 Human T-cell lymphotropic virus Species 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 3
- 230000015572 biosynthetic process Effects 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000002775 capsule Substances 0.000 description 3
- 239000013078 crystal Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- -1 i.e. Substances 0.000 description 3
- 238000010348 incorporation Methods 0.000 description 3
- 238000007911 parenteral administration Methods 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 239000000725 suspension Substances 0.000 description 3
- 230000009385 viral infection Effects 0.000 description 3
- QGZKDVFQNNGYKY-UHFFFAOYSA-N Ammonia Chemical compound N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 208000009889 Herpes Simplex Diseases 0.000 description 2
- 239000002202 Polyethylene glycol Substances 0.000 description 2
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 2
- 208000005074 Retroviridae Infections Diseases 0.000 description 2
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 2
- 208000036142 Viral infection Diseases 0.000 description 2
- 238000002441 X-ray diffraction Methods 0.000 description 2
- 239000000969 carrier Substances 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- 239000000945 filler Substances 0.000 description 2
- 239000008187 granular material Substances 0.000 description 2
- 230000002458 infectious effect Effects 0.000 description 2
- 238000002329 infrared spectrum Methods 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 150000004682 monohydrates Chemical class 0.000 description 2
- 125000003729 nucleotide group Chemical group 0.000 description 2
- 239000003921 oil Substances 0.000 description 2
- 229910052700 potassium Inorganic materials 0.000 description 2
- 239000011591 potassium Substances 0.000 description 2
- NASFKTWZWDYFER-UHFFFAOYSA-N sodium;hydrate Chemical compound O.[Na] NASFKTWZWDYFER-UHFFFAOYSA-N 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 235000010356 sorbitol Nutrition 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000002076 thermal analysis method Methods 0.000 description 2
- RWQNBRDOKXIBIV-UHFFFAOYSA-N thymine Chemical compound CC1=CNC(=O)NC1=O RWQNBRDOKXIBIV-UHFFFAOYSA-N 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- DNIAPMSPPWPWGF-GSVOUGTGSA-N (R)-(-)-Propylene glycol Chemical compound C[C@@H](O)CO DNIAPMSPPWPWGF-GSVOUGTGSA-N 0.000 description 1
- 241000416162 Astragalus gummifer Species 0.000 description 1
- 208000014644 Brain disease Diseases 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 241000701022 Cytomegalovirus Species 0.000 description 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 1
- 208000032274 Encephalopathy Diseases 0.000 description 1
- 241000713730 Equine infectious anemia virus Species 0.000 description 1
- 108010010803 Gelatin Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 229920000084 Gum arabic Polymers 0.000 description 1
- 241000700721 Hepatitis B virus Species 0.000 description 1
- 241000701044 Human gammaherpesvirus 4 Species 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 208000008771 Lymphadenopathy Diseases 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241001631646 Papillomaviridae Species 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- KDCGOANMDULRCW-UHFFFAOYSA-N Purine Natural products N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 1
- CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 1
- 206010038997 Retroviral infections Diseases 0.000 description 1
- 229920002472 Starch Polymers 0.000 description 1
- 229920001615 Tragacanth Polymers 0.000 description 1
- 206010046865 Vaccinia virus infection Diseases 0.000 description 1
- 239000000205 acacia gum Substances 0.000 description 1
- 235000010489 acacia gum Nutrition 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 208000013228 adenopathy Diseases 0.000 description 1
- 229910021529 ammonia Inorganic materials 0.000 description 1
- LFVGISIMTYGQHF-UHFFFAOYSA-N ammonium dihydrogen phosphate Chemical compound [NH4+].OP(O)([O-])=O LFVGISIMTYGQHF-UHFFFAOYSA-N 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 235000008452 baby food Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000003139 buffering effect Effects 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 125000002091 cationic group Chemical group 0.000 description 1
- 150000001768 cations Chemical group 0.000 description 1
- 238000002512 chemotherapy Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 201000003740 cowpox Diseases 0.000 description 1
- 230000000120 cytopathologic effect Effects 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- FMWAXKQEIXRUTI-UHFFFAOYSA-N dodecyl hydrogen sulfate;sodium Chemical compound [Na].CCCCCCCCCCCCOS(O)(=O)=O FMWAXKQEIXRUTI-UHFFFAOYSA-N 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 206010014599 encephalitis Diseases 0.000 description 1
- 150000002084 enol ethers Chemical class 0.000 description 1
- 150000002085 enols Chemical group 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 125000001033 ether group Chemical group 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 125000000524 functional group Chemical group 0.000 description 1
- 210000004051 gastric juice Anatomy 0.000 description 1
- 239000008273 gelatin Substances 0.000 description 1
- 229920000159 gelatin Polymers 0.000 description 1
- 235000019322 gelatine Nutrition 0.000 description 1
- 235000011852 gelatine desserts Nutrition 0.000 description 1
- 230000005802 health problem Effects 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 206010022000 influenza Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 239000000543 intermediate Substances 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 239000007927 intramuscular injection Substances 0.000 description 1
- 238000010255 intramuscular injection Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 238000010253 intravenous injection Methods 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 159000000003 magnesium salts Chemical class 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 230000014759 maintenance of location Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000002850 nasal mucosa Anatomy 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 238000000655 nuclear magnetic resonance spectrum Methods 0.000 description 1
- 239000002777 nucleoside Substances 0.000 description 1
- 229940127073 nucleoside analogue Drugs 0.000 description 1
- 125000003835 nucleoside group Chemical group 0.000 description 1
- 239000006186 oral dosage form Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 230000000750 progressive effect Effects 0.000 description 1
- 125000006239 protecting group Chemical group 0.000 description 1
- IGFXRKMLLMBKSA-UHFFFAOYSA-N purine Chemical compound N1=C[N]C2=NC=NC2=C1 IGFXRKMLLMBKSA-UHFFFAOYSA-N 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 208000023504 respiratory system disease Diseases 0.000 description 1
- 201000005404 rubella Diseases 0.000 description 1
- 239000000377 silicon dioxide Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000008107 starch Substances 0.000 description 1
- 235000019698 starch Nutrition 0.000 description 1
- 210000002784 stomach Anatomy 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 229940113082 thymine Drugs 0.000 description 1
- 239000000196 tragacanth Substances 0.000 description 1
- 235000010487 tragacanth Nutrition 0.000 description 1
- 229940116362 tragacanth Drugs 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- 239000001226 triphosphate Substances 0.000 description 1
- 235000011178 triphosphate Nutrition 0.000 description 1
- 125000002264 triphosphate group Chemical class [H]OP(=O)(O[H])OP(=O)(O[H])OP(=O)(O[H])O* 0.000 description 1
- 241001529453 unidentified herpesvirus Species 0.000 description 1
- 208000007089 vaccinia Diseases 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Landscapes
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US35206589A | 1989-05-15 | 1989-05-15 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| SK237290A3 SK237290A3 (en) | 1998-07-08 |
| SK279130B6 true SK279130B6 (sk) | 1998-07-08 |
Family
ID=23383649
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK2372-90A SK279130B6 (sk) | 1989-05-15 | 1990-05-15 | Vo vode vysoko rozpustná, stabilná kryštalická soľ |
| SK1273-97A SK279253B6 (sk) | 1989-05-15 | 1997-09-19 | Vo vode vysoko rozpustné, stabilné a kryštalické s |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SK1273-97A SK279253B6 (sk) | 1989-05-15 | 1997-09-19 | Vo vode vysoko rozpustné, stabilné a kryštalické s |
Country Status (11)
| Country | Link |
|---|---|
| JP (1) | JP2926257B2 (cg-RX-API-DMAC7.html) |
| CA (1) | CA2016765C (cg-RX-API-DMAC7.html) |
| CZ (1) | CZ9602347A3 (cg-RX-API-DMAC7.html) |
| DD (1) | DD298406A5 (cg-RX-API-DMAC7.html) |
| MY (1) | MY116824A (cg-RX-API-DMAC7.html) |
| NZ (1) | NZ233646A (cg-RX-API-DMAC7.html) |
| PL (1) | PL163999B1 (cg-RX-API-DMAC7.html) |
| SK (2) | SK279130B6 (cg-RX-API-DMAC7.html) |
| TW (1) | TW233301B (cg-RX-API-DMAC7.html) |
| YU (1) | YU92890A (cg-RX-API-DMAC7.html) |
| ZA (1) | ZA903662B (cg-RX-API-DMAC7.html) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7122207B2 (en) | 1998-05-22 | 2006-10-17 | Bristol-Myers Squibb Company | High drug load acid labile pharmaceutical composition |
| JP4731121B2 (ja) * | 2004-02-02 | 2011-07-20 | 協和発酵キリン株式会社 | キサンチン誘導体水和物 |
| WO2009119785A1 (ja) * | 2008-03-28 | 2009-10-01 | 浜理薬品工業株式会社 | エチニルチミジン化合物の精製方法 |
| JP5485140B2 (ja) * | 2008-04-10 | 2014-05-07 | 浜理薬品工業株式会社 | ５−メチルウリジンを出発原料とするエチニルチミジン化合物の製造方法 |
-
1990
- 1990-05-11 NZ NZ23364690A patent/NZ233646A/xx unknown
- 1990-05-11 YU YU92890A patent/YU92890A/sh unknown
- 1990-05-12 TW TW79103864A patent/TW233301B/zh active
- 1990-05-14 CA CA002016765A patent/CA2016765C/en not_active Expired - Fee Related
- 1990-05-14 ZA ZA903662A patent/ZA903662B/xx unknown
- 1990-05-14 MY MYPI90000768A patent/MY116824A/en unknown
- 1990-05-14 PL PL28517590A patent/PL163999B1/pl not_active IP Right Cessation
- 1990-05-15 SK SK2372-90A patent/SK279130B6/sk unknown
- 1990-05-15 JP JP12326390A patent/JP2926257B2/ja not_active Expired - Lifetime
- 1990-05-15 DD DD90340679A patent/DD298406A5/de unknown
-
1996
- 1996-08-08 CZ CZ19962347A patent/CZ9602347A3/cs not_active IP Right Cessation
-
1997
- 1997-09-19 SK SK1273-97A patent/SK279253B6/sk unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2926257B2 (ja) | 1999-07-28 |
| CA2016765A1 (en) | 1990-11-15 |
| CA2016765C (en) | 1997-10-21 |
| SK127397A3 (en) | 1998-08-05 |
| TW233301B (cg-RX-API-DMAC7.html) | 1994-11-01 |
| PL285175A1 (en) | 1991-01-14 |
| NZ233646A (en) | 1991-10-25 |
| PL163999B1 (pl) | 1994-06-30 |
| YU92890A (sh) | 1992-09-07 |
| CZ288463B6 (en) | 2001-06-13 |
| SK279253B6 (sk) | 1998-08-05 |
| JPH035477A (ja) | 1991-01-11 |
| DD298406A5 (de) | 1992-02-20 |
| CZ9602347A3 (en) | 2001-06-13 |
| SK237290A3 (en) | 1998-07-08 |
| MY116824A (en) | 2004-04-30 |
| ZA903662B (en) | 1991-01-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| FI87783B (fi) | Foerfarande foer framstaellning av terapeutiskt anvaendbara 2',3'-dideoxinukleosider | |
| CA1336088C (en) | 1-(3'-substitued-2', 3'-dideoxy-d-ribofuranosyl) thymine and uracil | |
| KR100225986B1 (ko) | 항바이러스성 누클레오시드 배합제 | |
| EP0322384B1 (en) | Nucleosides for use in therapy | |
| JP2540576B2 (ja) | 抗レトロウイルスおよびｂ型肝炎剤 | |
| US4710492A (en) | 3'-azido-2',3'-dideoxy-5-halouridine and its use in treating patients infected with retroviruses | |
| US5446029A (en) | Anti-retroviral activity of 2',3'-dideoxy-3'-fluoronucleosides | |
| JP2967998B2 (ja) | 新規なネプラノシン誘導体類 | |
| EP0421819A1 (en) | Therapeutic nucleosides | |
| EP0294443B1 (en) | Use of nucleosides for the manufacture of medicament for treatment of diseases caused by retrovirus or hepatitis b virus | |
| SK279130B6 (sk) | Vo vode vysoko rozpustná, stabilná kryštalická soľ | |
| US4920210A (en) | 2,6-diaminopurine-9-β-D-2',3'-dideoxyribofuranoside | |
| EP0361831B1 (en) | Antiviral nucleoside combination | |
| FI95269C (fi) | 2',3'-dideoksi-inosiinimonohydraatin, 2',3'-dideoksi-2',3'-didehydrot ymidiinimonohydraatin ja 2',3'-dideoksi-2'-fluori-inosiinihemihydraatin antiviraalisia, hyvin vesiliukoisia, stabiileja, kiteisiä suoloja | |
| US6207650B1 (en) | Antiviral, highly water soluble, stable, crystalline salts of 2′, 3′-dideoxyinosine, 2′, 3′-dideoxy-2′, 3′-didehydrothymidine and 2′, 3′-dideoxy-2′-fluoroinosine | |
| CZ288119B6 (cs) | Ve vodě rozpustná, stabilní krystalická sůl 2`,3`-dideoxy-2`,3`-didehydrothimidinu, způsob její přípravy a farmaceutický prostředek, který ji obsahuje | |
| RU2073007C1 (ru) | Способ получения устойчивой водорастворимой кристаллической соли 2,3-дидеоксиинозина | |
| CA1327005C (en) | Therapeutic nucleosides | |
| JPH04352755A (ja) | グリチルレチン酸誘導体を有効成分とする抗ウイルス剤 | |
| JPH09249565A (ja) | 抗ｈｉｖ活性を有するチアゾリジン化合物 | |
| JPH0662622B2 (ja) | 新規なジデオキシプリンヌクレオシド類、その製法およびそれを用いた抗ウイルス剤 | |
| CZ20002312A3 (cs) | Nová fosfátová sůl izopropylmethyl-[2-(3-npropoxyfenoxy)ethyl]aminu |